Navigation Links
PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
Date:8/29/2013

SCHOFIELD, Wis., Aug. 29, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that it will discuss LipiGesic M on Armed Forces Network.

Studies show that thirty-seven percent of military veterans who are returning from combat zones suffer with migraine; this ratio is three to four times greater than that of the general population. These veterans with migraine are twice as likely to suffer Post-Traumatic Stress Disorder (PTSD). This creates a hardship for these veterans since the medications that are commonly used to treat PTSD are incompatible with the prescription medications currently used to treat migraine.

"The drug interactions between the PTSD medications and current prescription migraine treatments can be deadly," said Russ Mitchell, CEO of PuraMed BioScience. "We offer these veterans a highly effective alternative to treat their migraines since LipiGesic M has an excellent safety profile and has no reported drug interactions. It is important for veterans suffering both conditions to find treatment, since the symptoms of one will increase the symptoms of the other causing a vicious cycle. With LipiGesic M, veterans are now safe to treat migraine without having to sacrifice their treatment for PTSD."

LipiGesic M is an over-the-counter formulation of feverfew and ginger that has been clinically tested and found to provide rapid-relief from migraine headache and associated symptoms. When clinical trial results of LipiGesic M are compared to those of prescription medications, LipiGesic M is found to be as effective as the top-selling prescription migraine medication, but without the severe effects.

"We are honored that Armed Forces Network requested two interviews with us after they heard our broadcasts on the Big Biz Show," said Mitchell. "We know that LipiGesic M has been well received by the troops and has been battle tested on the frontlines in Afghanistan. It quickly became one of the most requested items in the care packages that were sent to the front. Since it does not cause severe or debilitating side effects, military personnel can take LipiGesic M and get back to the important work of defending our country."

About PuraMed BioScience, Inc.

PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch LipiGesic H for tension-type headaches and LipiGesic PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com

Forward-Looking Statements

This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
Patricia McMurtrie
PuraMed BioScience
1326 Schofield Avenue
Schofield, WI 54476
715-571-4910
patricia@puramedbioscience.com


'/>"/>
SOURCE PuraMed BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
2. PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
3. Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013
4. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
5. Sangamo BioSciences to Acquire Ceregene
6. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
7. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
8. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
9. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
10. Novel Use of Pressure BioSciences Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design
11. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
Breaking Medicine News(10 mins):